THERAPEUTIC AREA

Metabolic

Metabolic
425

million adult people

in the world are living with diabetes, with Type 2 diabetes accounting for 90% of all cases1

About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases1. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.
 

1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (link is external) (accessed Apr 2018)


Learn more
 
Metabolic
Respiratory
 

Respiratory

Respiratory
Boehringer Ingelheim
has over 90 years
of heritage
in managing
respiratory disease

Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life

 
Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.

Learn more

EXPLORE OUR CONTENT

What is the leading cause of death in T2D? 01:32
11/12/2018
Author: Boehringer Ingelheim

What is the leading cause of death in T2D?

Despite advances in care, CV disease is still the #1 cause of death in type 2 diabetes1

Ofev Management Guide

icoPDF

11/12/2018
Author: Boehringer Ingelheim

Ofev Management Guide

Treatment of Idiopathic Pulmonary Fibrosis with OFEVTM